|
| 37543510 | Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone. | | 2023 |
| 36251745 | Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma. | Blood Adv | 2023 |
| 35443559 | The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. | Haematologica | 2023 |
| 36008121 | First-in-Humans Evaluation of Safety and Dosimetry of <sup>64</sup>Cu-LLP2A for PET Imaging. | J Nucl Med | 2023 |
| 37597685 | Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell Transplantation. | Transplant Cell Ther | 2023 |
| 37659966 | Disparities in Multiple Myeloma Treatment Patterns in the United States: A Systematic Review. | Clin Lymphoma Myeloma Leuk | 2023 |
| 37741459 | Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter Trial. | | 2023 |
| 37914932 | Epigenetic regulation during cancer transitions across 11 tumour types. | Nature | 2023 |
| 37559718 | Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM. | Front Immunol | 2023 |
| 36779841 | Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma. | Cancer Res | 2023 |
| 36762851 | Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. | | 2023 |
| 36702834 | Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma. | NPJ Genom Med | 2023 |
| 37069359 | Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. | Nat Med | 2023 |
| 36754693 | The Dynamics of Financial Toxicity in Multiple Myeloma. | | 2023 |
| 36801522 | Evaluation of the Simplified Score to Predict Early Relapse in Multiple Myeloma (S-ERMM) in the MMRF CoMMpass study. | | 2023 |
| 37164972 | Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study. | | 2023 |
| 34996933 | Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival. | Sci Rep | 2022 |
| 36029527 | A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen ÿ CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. | Journal of Clinical Oncology | 2022 |
| 35422095 | CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells. | Leukemia | 2022 |
| 36114265 | Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma. | Leukemia | 2022 |
| 35598841 | Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality. | Transplant Cell Ther | 2022 |
| 36969740 | Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis. | Cancer Res Commun | 2022 |
| 34802043 | Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. | Leukemia | 2022 |
| 35332278 | LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. | Leukemia | 2022 |
| 35024768 | Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. | JAMA Oncol | 2022 |
| 34844892 | POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis. | Clinical Lymphoma, Myeloma and Leukemia | 2022 |
| 34840088 | Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. | Clinical Lymphoma, Myeloma and Leukemia | 2022 |
| 34588522 | A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma. | Sci Rep | 2021 |
| 33963182 | Co-evolution of tumor and immune cells during progression of multiple myeloma. | Nat Commun | 2021 |
| 33479469 | Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy. | Leukemia | 2021 |
| 33475778 | Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world". | Annals of Hematology | 2021 |
| 33467957 | A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes. | Leuk Lymphoma | 2021 |
| 34110937 | Evolving Paradigms of Therapy for Multiple Myeloma: State of the Art and Future Directions. | JCO Oncology Practice | 2021 |
| 34142630 | A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma. | Leukemia and Lymphoma | 2021 |
| 34036230 | Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia. | JCO Precis Oncol | 2021 |
| 33875814 | Autologous stem cell transplant for patients with multiple myeloma between ages 75 and 78. | Bone Marrow Transplantation | 2021 |
| 34251414 | Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). | Blood Adv | 2021 |
| 33980831 | A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. | Blood Cancer Journal | 2021 |
| 33927193 | Correction: Allogeneic transplantation in elderly patients â¿¥65 years with non-Hodgkin lymphoma: a time-trend analysis. | Blood Cancer Journal | 2021 |
| 34333962 | Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. | Haematologica | 2021 |
| 32974944 | Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. | American Journal of Hematology | 2021 |
| 33355244 | VLA4-Targeted Nanoparticles Hijack Cell Adhesion-Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival. | Clin Cancer Res | 2021 |
| 33080623 | Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. | Blood | 2021 |
| 32966625 | African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. | Cancer | 2021 |
| 34488662 | Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. | BMC Cancer | 2021 |
| 31462683 | Maintenance therapy following salvage autologous stem cell transplant in patients with multiple myeloma. | Bone Marrow Transplantation | 2020 |
| 32325171 | Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma. | Biol Blood Marrow Transplant | 2020 |
| 31969330 | First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. | Clinical Cancer Research | 2020 |
| 32315239 | Newly Diagnosed Myeloma in 2020. | American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting | 2020 |
| 32130471 | DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma. | Annals of Hematology | 2020 |